Patents by Inventor J. Yun Tso

J. Yun Tso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150274832
    Abstract: The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.
    Type: Application
    Filed: June 9, 2015
    Publication date: October 1, 2015
    Inventors: Taymar E. HARTMAN, Paul W. Sauer, John E. Burky, Mark C. Wesson, Ping Y. Huang, Thomas J. Robinson, Braeden D. Partridge, J. Yun Tso
  • Publication number: 20150203583
    Abstract: The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.
    Type: Application
    Filed: January 21, 2015
    Publication date: July 23, 2015
    Inventors: Taymar E. HARTMAN, Paul W. Sauer, John E. Burky, Mark C. Wesson, Ping Y. Huang, Thomas J. Robinson, Braeden D. Partridge, J. Yun Tso
  • Publication number: 20150197573
    Abstract: The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 16, 2015
    Inventors: Taymar E. HARTMAN, Paul W. Sauer, John E. Burky, Mark C. Wesson, Ping Y. Huang, Thomas J. Robinson, Braeden D. Partridge, J. Yun Tso
  • Patent number: 9028830
    Abstract: The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: May 12, 2015
    Assignee: JN Biosciences, LLC
    Inventors: J. Yun Tso, Naoya Tsurushita, Nicholas F. Landolfi, Shankar Kumar
  • Patent number: 9006399
    Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: April 14, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
  • Publication number: 20150073130
    Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Applicant: JN BIOSCIENCE LLC
    Inventors: J. Yun Tso, Naoya Tsurushita
  • Patent number: 8969539
    Abstract: This present invention provides an expression vector system that uses alternative RNA processing to express in a single cell a polypeptide in both membrane-bound and soluble forms. By incorporating a mimetic structure of the 3? terminal region of human mu gene and introducing other exogenous genetic elements, an artificial gene can be constructed that is capable of simultaneously expressing membrane-bound and secreted forms of polypeptides in myeloma cells and other cells of the B lymphocyte lineage, as well as in non-B cells. If an immunoglobulin heavy chain is co-expressed with a light chain using this vector, whole antibodies can be produced that are both displayed on the surface of a single cell and secreted into the cell culture supernatant. Membrane-bound antibodies facilitate isolation and expansion of those cells displaying antibodies with desired antigen binding characteristics, while secreted antibodies facilitate identification of antibodies having desired biological function(s).
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: March 3, 2015
    Assignee: JN Biosciences LLC
    Inventors: Naoya Tsurushita, J. Yun Tso
  • Patent number: 8952134
    Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: February 10, 2015
    Assignee: JN Biosciences LLC
    Inventors: J. Yun Tso, Naoya Tsurushita
  • Publication number: 20150038682
    Abstract: The invention provides antibodies or fusion proteins with modified heavy chain IgG constant regions that promote assembly of multimeric complexes. Within an antibody or fusion protein unit there are two heavy chains each including at least CH2 and CH3 regions. The two heavy chains bear complementary modifications (e.g., knob and hole) to promote coupling of the heavy chains within a unit. One and only one of the heavy chains in a unit is fused at its C-terminus to a homomultimerizing peptide. The presence of the homomultimerizing peptide promotes association between units. For example, if the homomultimerizing peptide is a homotrimerizing peptide it promotes association of three units to form a trimeric complex.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Applicant: JN BIOSCIENCES LLC
    Inventors: Naoya Tsurushita, J. Yun Tso
  • Publication number: 20150004178
    Abstract: Anti-human sema4A antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4A antibodies can inhibit T cell proliferation and Th2 differentiation induced by IL-4, anti-CD3, anti-CD28 and recombinant sema4A.
    Type: Application
    Filed: October 5, 2012
    Publication date: January 1, 2015
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Yong-Jun Liu, Ning Lu, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
  • Publication number: 20140308276
    Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
    Type: Application
    Filed: February 9, 2012
    Publication date: October 16, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
  • Publication number: 20140294825
    Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 2, 2014
    Applicant: JN Biosciences LLC
    Inventors: J. Yun Tso, Naoya Tsurushita
  • Publication number: 20140294845
    Abstract: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.
    Type: Application
    Filed: February 3, 2014
    Publication date: October 2, 2014
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: J. Yun Tso, Anton Wellstein, Debra Chao
  • Publication number: 20140295497
    Abstract: The present disclosure is directed to expression vectors, comprising a weakened SV40 promoter, and recombinant mammalian cells capable of producing high levels of a polypeptide of interest, methods of generating and using such recombinant mammalian cells.
    Type: Application
    Filed: November 30, 2011
    Publication date: October 2, 2014
    Inventors: Taymar E. Hartman, J. Yun Tso, Yimin He
  • Patent number: 8821863
    Abstract: The present invention provides humanized antibodies that immunospecifically recognize human ?9 integrin. Some of these antibodies inhibit the biological functions of the ?9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with ?9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: September 2, 2014
    Assignees: Gene Techno Science Co., Ltd., Kaken Pharmaceutical Co.
    Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Shigeyuki Kon
  • Patent number: 8735552
    Abstract: The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: May 27, 2014
    Assignees: Gene Techno Science Co., Ltd., Kaken Pharmaceutical Co.
    Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Tatsuhiro Harada
  • Publication number: 20140065063
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: May 15, 2013
    Publication date: March 6, 2014
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Publication number: 20140037621
    Abstract: The invention provides constant regions incorporating a cysteine mutation and linked to a ? tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and ? tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.
    Type: Application
    Filed: July 31, 2013
    Publication date: February 6, 2014
    Applicant: JN Biosciences LLC
    Inventors: Naoya Tsurushita, J. Yun Tso
  • Patent number: 8617829
    Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: December 31, 2013
    Assignee: Gene Techno Science Co., Ltd.
    Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita
  • Patent number: 8614296
    Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: December 24, 2013
    Assignee: Gene Techno Science Co., Ltd.
    Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Shigeyuki Kon, Toshimitsu Uede